A PHASE 1, SINGLE-ARM, OPEN-LABEL, NON-RANDOMIZED, NON-CONTROLLED MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF A SINGLE SUBCUTANEOUS DOSE OF PF-06741086 IN CHINESE ADULT PARTICIPANTS WITH SEVERE HEMOPHILIA
Latest Information Update: 11 Jul 2023
At a glance
- Drugs Marstacimab (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors Pfizer
- 03 Sep 2021 Status changed from recruiting to completed.
- 02 Jun 2021 Planned End Date changed from 23 Aug 2021 to 24 Aug 2021.
- 02 Jun 2021 Planned primary completion date changed from 23 Aug 2021 to 24 Aug 2021.